VALUENCE
16.7.2021 10:56:09 CEST | Business Wire | Press release
Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director and president), a member of the Valuence Group (TOKYO:9270), announced on July 1, the launch of the official version of its winning bid market price chart, available by subscription. The official version of the service has been upgraded and comes with new, useful features. Star Buyers Auction is a luxury brand goods auction service operated by Valuence Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005104/en/
New Features and Upgrades Reflect Partner Input
The Valuence Japan-operated Star Buyers Auction is a pre-owned luxury branded goods B2B auction and the main sales channel of the Valuence Group. Since the launch of Star Buyers Auction, the service has continued to grow in scale, adding new categories and offering new services, including online global auctions. In February 2021, Valuence Japan introduced a beta version of a market price chart subscription service for use by partners around the world. This service displays global market prices (actual winning auction bids) for a variety of goods. The company received abundant and valuable feedback from its partners regarding bidding and consignment sales, at the same time attracting an increasing number of new subscribers.
Valuence Japan added new functions to the Star Buyers Auction market price chart subscription service, incorporating feedback from partners. The company released the official upgraded version of the service on July 1. At the same time, the company will continue to look at upgrading the service based on feedback, striving to create a global reuse platform serving as an indispensable part of the purchasing and selling markets.
Official Version and Upgrades
The official version of the market price chart service now allows users to enter multiple search terms, including brand and model names. This powerful upgrade reduces time spent in search for specific products. Users may also conduct searches by transaction date range, providing a narrower view of the vast amount of transaction data available. The search results screen now displays accessories, prices, and transaction dates in either ascending or descending order. Here, users will be able to sort through information, including accessories, price ranges, and other data for multiple products. Search results draw on the more than 25,000 items sold every auction, demonstrating the vast amount of valuable market data accumulated by Star Buyers Auction.
Valuence Japan is confident that the upgraded version of this service will deliver the type of market price information needed and used by the B2B auction partners.
Star Buyers Auction Overview
A luxury brand goods auction for reuse business dealers, launched in April 2013. In April 2020, auctions were migrated to a fully online format, listing a constantly stable stream of luxury items both in quantity and quality. Listings primarily focus on watches, bags, and brand jewelry procured by the Valuence Group. Auctions are held twice monthly. Market price chart subscription service is also available for 11,000 yen per month.
Official Site: https://biz.starbuyers-global-auction.com/en/
Youtube: https://youtu.be/efUtXrO9JkE
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005104/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom